Inhibition of Interleukin-1β Signaling by Anakinra Demonstrates a Critical Role of Bone Loss in Experimental Arthritogenic Alphavirus Infections.
Stefan WolfAdam TaylorAli ZaidJoseph FreitasLara J HerreroShambhavi RaoAndreas SuhrbierMark R ForwoodRichard BucalaSuresh MahalingamPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
The present findings suggest that anakinra therapy may reduce bone loss in experimental murine models of RRV and CHIKV. Further investigations are needed to assess the potential therapeutic benefits of anakinra in patients with arthritogenic alphavirus disease.